Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Porst H, et al. Among authors: esler a. J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19. J Sex Med. 2013. PMID: 23782459 Clinical Trial.
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ. Egerdie RB, et al. J Sex Med. 2012 Jan;9(1):271-81. doi: 10.1111/j.1743-6109.2011.02504.x. Epub 2011 Oct 7. J Sex Med. 2012. PMID: 21981682 Clinical Trial.
Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial.
Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, Da Pozzo L, Esler A, Cox D. Pinggera GM, et al. Among authors: esler a. Urology. 2014 Aug;84(2):412-9. doi: 10.1016/j.urology.2014.02.063. Epub 2014 Jun 14. Urology. 2014. PMID: 24938580 Clinical Trial.
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C, Oelke M, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Büttner H. Vlachopoulos C, et al. Among authors: esler a. Int J Clin Pract. 2015 Dec;69(12):1496-507. doi: 10.1111/ijcp.12722. Epub 2015 Aug 24. Int J Clin Pract. 2015. PMID: 26299520 Clinical Trial.
Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8].
Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. Gazzah A, et al. Among authors: esler a. Eur J Cancer. 2019 Sep;119:198. doi: 10.1016/j.ejca.2018.12.018. Epub 2019 Jul 30. Eur J Cancer. 2019. PMID: 31375258 No abstract available.
79 results